View Financial HealthGreen Star Products 배당 및 자사주 매입배당 기준 점검 0/6Green Star Products 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 22Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 800,000,000 Price\Range: $0.0025 Discount Per Security: $0공시 • Mar 12Green Star Products, Inc. Appoints Miss Kristy as New PresidentGreen Star Products, Inc. announced it now has a new president. Miss Kristy Hunt has been appointed President of Green Star Products, Inc.공시 • Feb 27Green Star Products Announces Approving the Exclusive Licensing with Biotech ResearchMr. Joseph LaStella, President of Green Star Products, Inc. stated, “The Company has enough early votes to close the COVID-19 contract with BTR (Biotech Research, LLC).” The Company has already received 52% of shareholder’s votes, and over 90% have voted in favor of approving the exclusive licensing with Biotech Research. This approval ensures the final passage of the contract between Green Star Products and Biotech Research at the shareholders meeting. GSPI can now move ahead with this exclusive distribution agreement. For more details, please see press release dated December 21, 2020, titled: "Green Star Products: New Research Data Indicates 99.9% Effective Against The COVID-19 Virus.” The 2021 Special Shareholders Meeting is scheduled on March 3, 2021. Due to the COVID-19 pandemic, Green Star Products will not be holding an actual in-person stockholders meeting. In that web page can find a Letter to Stockholders with current information about Company operations, voting updates, and a Special Shareholder’s Discount Coupon Code for Viro Spectrum Shield (VSS) purchases and some information about this great anti-viral product. At the present time, Company is concentrating all its efforts on distribution of Viro Spectrum Shield, as it is of utmost importance that help save lives during this active pandemic. COVID-19 is mutating quickly and spreading throughout the world. VSS has been successfully tested against multiple viruses. It tested at 99.9% efficacy against the COVID-19 virus in vitro. Results verified by a United States Federally Accredited Laboratory prove that VSS is non-toxic and has shown Broad-Spectrum Antiviral capabilities. So many benefits to VSS, none more important than this formula can be used to combat the virus after infection as well as an all-natural preventative. Volunteers who were ill as a result of virus, many testing positive for the COVID-19 virus, used VSS and showed reversal of symptoms in 24-72 hours. See https://vssmt.net/for more information. VSS makes no claims, the evidence speaks for itself.공시 • Dec 20Green Star Products, Inc. Announces New Research Data Indicates 99.9% Effective Against the COVID-19 VirusGreen Star Products, Inc. announced it received new data from a US Federally Accredited Laboratory stating, "In three replications at 3% and 10% concentration [of normal dosage of Viro Spectrum Shield], 100% of the cells were protected from signs of infection by the SARS-CoV-2 [COVID-19] virus, in vitro". Additionally, Viro Spectrum Shield (VSS) was specifically tested and found to be effective against the COVID-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Furthermore, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for COVID-19, have experienced significantly improved health and reduction or elimination of symptoms usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization. Viro Spectrum Shield is a proprietary blend of natural herbs and native plants. Presently, the blend is considered a dietary supplement.공시 • Dec 13Green Star Products Signs Covid-19 Distribution ContractGreen Star Products, Inc. has signed a Distribution Contract with Biotech Research, LLC, to market/sell their Broad-Spectrum Antiviral Product, called Viro Spectrum Shield (VSS), in several South American countries. VSS has been tested by a US Federally Accredited Laboratory and has been successfully proven to inhibit SARS-CoV-2 (Covid-19) virus in vitro. VSS was specifically tested and found to be effective against the Covid-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Additionally, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for Covid-19, have experienced Significantly Improved Health and Reduction of Symptoms (or Elimination) usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 GSPI 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: GSPI 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Green Star Products 배당 수익률 vs 시장GSPI의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (GSPI)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Chemicals)1.7%분석가 예측 (GSPI) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 GSPI 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 GSPI 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 GSPI 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: GSPI 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 16:44종가2026/05/21 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Green Star Products, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 22Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 800,000,000 Price\Range: $0.0025 Discount Per Security: $0
공시 • Mar 12Green Star Products, Inc. Appoints Miss Kristy as New PresidentGreen Star Products, Inc. announced it now has a new president. Miss Kristy Hunt has been appointed President of Green Star Products, Inc.
공시 • Feb 27Green Star Products Announces Approving the Exclusive Licensing with Biotech ResearchMr. Joseph LaStella, President of Green Star Products, Inc. stated, “The Company has enough early votes to close the COVID-19 contract with BTR (Biotech Research, LLC).” The Company has already received 52% of shareholder’s votes, and over 90% have voted in favor of approving the exclusive licensing with Biotech Research. This approval ensures the final passage of the contract between Green Star Products and Biotech Research at the shareholders meeting. GSPI can now move ahead with this exclusive distribution agreement. For more details, please see press release dated December 21, 2020, titled: "Green Star Products: New Research Data Indicates 99.9% Effective Against The COVID-19 Virus.” The 2021 Special Shareholders Meeting is scheduled on March 3, 2021. Due to the COVID-19 pandemic, Green Star Products will not be holding an actual in-person stockholders meeting. In that web page can find a Letter to Stockholders with current information about Company operations, voting updates, and a Special Shareholder’s Discount Coupon Code for Viro Spectrum Shield (VSS) purchases and some information about this great anti-viral product. At the present time, Company is concentrating all its efforts on distribution of Viro Spectrum Shield, as it is of utmost importance that help save lives during this active pandemic. COVID-19 is mutating quickly and spreading throughout the world. VSS has been successfully tested against multiple viruses. It tested at 99.9% efficacy against the COVID-19 virus in vitro. Results verified by a United States Federally Accredited Laboratory prove that VSS is non-toxic and has shown Broad-Spectrum Antiviral capabilities. So many benefits to VSS, none more important than this formula can be used to combat the virus after infection as well as an all-natural preventative. Volunteers who were ill as a result of virus, many testing positive for the COVID-19 virus, used VSS and showed reversal of symptoms in 24-72 hours. See https://vssmt.net/for more information. VSS makes no claims, the evidence speaks for itself.
공시 • Dec 20Green Star Products, Inc. Announces New Research Data Indicates 99.9% Effective Against the COVID-19 VirusGreen Star Products, Inc. announced it received new data from a US Federally Accredited Laboratory stating, "In three replications at 3% and 10% concentration [of normal dosage of Viro Spectrum Shield], 100% of the cells were protected from signs of infection by the SARS-CoV-2 [COVID-19] virus, in vitro". Additionally, Viro Spectrum Shield (VSS) was specifically tested and found to be effective against the COVID-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Furthermore, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for COVID-19, have experienced significantly improved health and reduction or elimination of symptoms usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization. Viro Spectrum Shield is a proprietary blend of natural herbs and native plants. Presently, the blend is considered a dietary supplement.
공시 • Dec 13Green Star Products Signs Covid-19 Distribution ContractGreen Star Products, Inc. has signed a Distribution Contract with Biotech Research, LLC, to market/sell their Broad-Spectrum Antiviral Product, called Viro Spectrum Shield (VSS), in several South American countries. VSS has been tested by a US Federally Accredited Laboratory and has been successfully proven to inhibit SARS-CoV-2 (Covid-19) virus in vitro. VSS was specifically tested and found to be effective against the Covid-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Additionally, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for Covid-19, have experienced Significantly Improved Health and Reduction of Symptoms (or Elimination) usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization.